Avenda Health Inc.

Avenda Health Inc. develops Unfold AI, an FDA-cleared artificial intelligence platform for prostate cancer diagnosis and treatment planning. The software generates Cancer Estimation Maps (CEMs) that use machine learning to precisely visualize prostate cancer location and extent in three dimensions, leveraging patient-standard-of-care data including MRI, fusion biopsy, pathology results, and PSA levels. Unfold AI is designed to help urologists and oncologists select appropriate treatment modalities—including active surveillance, prostatectomy, focal therapy, and radiotherapy—while minimizing morbidity and improving cancer-free outcomes. Clinical validation demonstrates superior accuracy compared to MRI alone, with published research showing patients treated with Unfold AI margins are 71% more likely to be cancer-free. The platform is available exclusively through U.S. healthcare providers to patients with Gleason Grade 2 or higher prostate cancer who have not yet initiated treatment. Avenda Health operates on a provider-based distribution model and is actively working to expand insurance coverage and standardize pricing nationwide.